Moderna posts earnings beat but stock slips because it still doesn’t really have a product to sell
Moderna slipped in premarket trading despite beating Wall Street earnings estimates, as sales for the COVID-19 vaccine, its largest revenue driver, have slowed.
Moderna reported a loss per share of $2.52, better than the $3.12 loss per share analysts polled by FactSet were expecting. The company also reported $108 million in revenue, more than the $106.2 million analysts predicted. Its revenue was the lowest it’s been since June 2020, before its COVID-19 vaccine was on the market.
Moderna was able to make up for slowing sales by cutting costs. The company said it would cut $1.5 billion in costs by 2027, while still upping its investment in oncology research.